Commentary
Article
Top 5 Pharmacy Times Biosimilar Articles of 2023
From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.
1. Sandoz Launches Citrate-Free Adalimumab-Adaz as Biosimilar for Humira
Adalimumab-adaz HCF in the 100 mg/mL strength is approved for indications that are no longer covered exclusively for the reference Humira after July 2023. Read More Here.
2. The Rise of AI in Pharmacy Practice Presents Benefits and Challenges
Pharmacists must carefully consider safety concerns and patient privacy. Read More Here.
3. Act4Biosimilars Action Plan Seeks to Increase Patient Access to Biosimilars Globally
The Act4Biosimilars Action Plan highlights major challenges in promoting access to biosimilars and actionable steps to accelerate adoption. Read More Here.
4. Confusion Persists Around the Interchangeability Designation for Biosimilars
The legal and common uses of “interchangeability” continue to be conflated. Read More Here.
5. Biosimilars Increasingly Being Added to PBM Formularies
Express Scripts recently announced the addition of 3 Humira biosimilars to its main formulary. Read More Here.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
